Work

Phase Ib/II with expansion of patients at the MTD study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.5527

Authors: Saul E. Rivkin, Desiree Iriarte, Heather Sloan, Cara Wiseman, James Moon

Institutions: Rivkin Center for Ovarian Cancer, Fred Hutch Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2907242813

Cites:

Cited by: 12

Related to: 10